Susceptibility of meropenem and comparators tested against 30,634 enterobacteriaceae isolated in the MYSTIC programme (1997–2003)

This publication has 16 references indexed in Scilit:

• In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-esbl producing klebsiella pneumoniae
  Diagnostic Microbiology and Infectious Disease, 2004
• Ambler Class A Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella spp. in Canadian Hospitals
  Antimicrobial Agents and Chemotherapy, 2004
• Antibiotic Resistance Among Gram-Negative Bacilli in US Intensive Care Units
  JAMA, 2003
• Antimicrobial activity of broad-spectrum agents tested against gram-negative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)
  Diagnostic Microbiology and Infectious Disease, 2002
• Ciprofloxacin resistance--early-warning' signs from the MYSTIC surveillance programme?
  Journal of Antimicrobial Chemotherapy, 2002
• Antimicrobial Resistance in Gram-Negative Isolates from European Intensive Care Units: Data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme
  Journal of Chemotherapy, 2002
• Resistance Patterns Among Nosocomial Pathogens
  Chest, 2001
• Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997–1998
  Journal of Antimicrobial Chemotherapy, 2000
• Inadequate Antimicrobial Treatment of Infections
  Chest, 1999
• Antibiotic Susceptibility Among Aerobic Gram-negative Bacilli in Intensive Care Units in 5 European Countries
  JAMA, 1999